Your browser doesn't support javascript.
loading
Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study.
Meyer, Thomas; Dreger, Marie; Grehl, Torsten; Weyen, Ute; Kettemann, Dagmar; Weydt, Patrick; Günther, René; Lingor, Paul; Petri, Susanne; Koch, Jan Christoph; Großkreutz, Julian; Rödiger, Annekathrin; Baum, Petra; Hermann, Andreas; Prudlo, Johannes; Boentert, Matthias; Weishaupt, Jochen H; Löscher, Wolfgang N; Dorst, Johannes; Koc, Yasemin; Bernsen, Sarah; Cordts, Isabell; Vidovic, Maximilian; Steinbach, Robert; Metelmann, Moritz; Kleinveld, Vera E; Norden, Jenny; Ludolph, Albert; Walter, Bertram; Schumann, Peggy; Münch, Christoph; Körtvélyessy, Péter; Maier, André.
Afiliación
  • Meyer T; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Dreger M; Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.
  • Grehl T; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Weyen U; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Alfried Krupp Krankenhaus, Essen, Germany.
  • Kettemann D; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany.
  • Weydt P; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Günther R; Department for Neuromuscular Disorders, Bonn University, Bonn, Germany.
  • Lingor P; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
  • Petri S; Department of Neurology, Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Koch JC; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Dresden, Germany.
  • Großkreutz J; Department of Neurology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany.
  • Rödiger A; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Munich, Germany.
  • Baum P; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Hermann A; Department of Neurology, Universitätsmedizin Göttingen, Göttingen, Germany.
  • Prudlo J; Department of Neurology, Universitätsmedizin Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  • Boentert M; Department of Neurology, Jena University Hospital, Jena, Germany.
  • Weishaupt JH; Zentrum für Seltene Erkrankungen (ZSE), Jena University Hospital, Jena, Germany.
  • Löscher WN; Department of Neurology, University Hospital Leipzig, Leipzig, Germany.
  • Dorst J; Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University of Rostock, University Medical Center, Rostock, Germany.
  • Koc Y; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Greifswald, Germany.
  • Bernsen S; Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University of Rostock, University Medical Center, Rostock, Germany.
  • Cordts I; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Greifswald, Germany.
  • Vidovic M; Department of Neurology, Münster University Hospital, Münster, Germany.
  • Steinbach R; Division for Neurodegenerative Diseases, Neurology Department, Mannheim Center for Translational Medicine, University Medicine Mannheim, Heidelberg University, Mannheim, Germany.
  • Metelmann M; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
  • Kleinveld VE; Department of Neurology, Ulm University, Ulm, Germany.
  • Norden J; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Ulm, Germany.
  • Ludolph A; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Walter B; Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Schumann P; Department for Neuromuscular Disorders, Bonn University, Bonn, Germany.
  • Münch C; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
  • Körtvélyessy P; Department of Neurology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany.
  • Maier A; Department of Neurology, Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany.
Eur J Neurol ; 31(9): e16379, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38859579
ABSTRACT

OBJECTIVE:

To assess the performance of serum neurofilament light chain (sNfL) in clinical phenotypes of amyotrophic lateral sclerosis (ALS).

METHODS:

In 2949 ALS patients at 16 ALS centers in Germany and Austria, clinical characteristics and sNfL were assessed. Phenotypes were differentiated for two anatomical determinants (1) upper and/or lower motor involvement (typical, typMN; upper/lower motor neuron predominant, UMNp/LMNp; primary lateral sclerosis, PLS) and (2) region of onset and propagation of motor neuron dysfunction (bulbar, limb, flail-arm, flail-leg, thoracic onset). Phenotypes were correlated to sNfL, progression, and survival.

RESULTS:

Mean sNfL was - compared to typMN (75.7 pg/mL, n = 1791) - significantly lower in LMNp (45.1 pg/mL, n = 413), UMNp (58.7 pg/mL n = 206), and PLS (37.6 pg/mL, n = 84). Also, sNfL significantly differed in the bulbar (92.7 pg/mL, n = 669), limb (64.1 pg/mL, n = 1305), flail-arm (46.4 pg/mL, n = 283), flail-leg (53.6 pg/mL, n = 141), and thoracic (74.5 pg/mL, n = 96) phenotypes. Binary logistic regression analysis showed highest contribution to sNfL elevation for faster progression (odds ratio [OR] 3.24) and for the bulbar onset phenotype (OR 1.94). In contrast, PLS (OR 0.20), LMNp (OR 0.45), and thoracic onset (OR 0.43) showed reduced contributions to sNfL. Longitudinal sNfL (median 12 months, n = 2862) showed minor monthly changes (<0.2%) across all phenotypes. Correlation of sNfL with survival was confirmed (p < 0.001).

CONCLUSIONS:

This study underscored the correlation of ALS phenotypes - differentiated for motor neuron involvement and region of onset/propagation - with sNfL, progression, and survival. These phenotypes demonstrated a significant effect on sNfL and should be recognized as independent confounders of sNfL analyses in ALS trials and clinical practice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fenotipo / Proteínas de Neurofilamentos / Esclerosis Amiotrófica Lateral Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fenotipo / Proteínas de Neurofilamentos / Esclerosis Amiotrófica Lateral Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Eur J Neurol Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido